GNI Group Ltd. - 27 Oct 2023 Form 4 Insider Report for GYRE THERAPEUTICS, INC. (GYRE)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CBIO	Series X Convertible Preferred Stock	Purchase	$3,986,065	+811	+6.6%	$4915.00^*	13,151	27 Oct 2023	Common Stock	811,000		See Footnote	F1, F2, F3
transaction	CBIO	Series X Convertible Preferred Stock Warrant (Right to Buy)	Purchase	$1,013,788	+8,110,300		$0.1250	8,110,300	27 Oct 2023	Series X Convertible Preferred Stock	811		See Footnote	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Shares of Series X Convertible Preferred Stock of the Issuer, par value $0.001 per share (the "Preferred Stock"), are convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for the Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on December 27, 2022).
F2	The Preferred Stock has no expiration date.
F3	These securities are held by GNI USA, Inc., a Delaware corporation ("GNI USA") which is a wholly-owned subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability ("GNI Japan"). GNI Japan may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the securities held by GNI USA.
F4	These warrants have an exercise price of $4,915.00 per share of Preferred Stock.